A look back at this week's news.
Women who underwent a frozen-thawed embryo transfer (FET) for assisted reproductive technology (ART) treatment were nearly twice as likely to experience bleeding or miscarriage in the first trimester with hormone replacement cycles (HRC-FET) compared to natural cycles (NC-FET), according to a retrospective cohort study published in the European Journal of Obstetrics & Gynecology and Reproductive Biology.
What we know so far about remote therapeutic monitoring, remote patient monitoring and preventive services.
Chromosomal abnormalities in infertile couples who use assisted reproductive technology (ART) do not appear to impact cumulative clinical pregnancy or live-birth rates, according to a study published in the Annals of Medicine.
A substudy of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial, which compared three highly effective, reversible methods of contraception, concluded that women assigned either a copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant may have had condomless sex more frequently than women assigned to intramuscular depo-medroxyprogesterone acetate (DMPA-IM).
The US Food and Drug Administration recently updated its guidelines for dispensing mifepristone (the “abortion pill”) to now include certified pharmacies.